Withings Achieves Profitability in 2025 with 90% Growth Since 2018

Withings today announced that it has achieved profitability for the full year 2025. Since 2018, the company has grown its global revenue by approximately 90%, with France and Germany as key European markets.

With 66% of its 2025 revenue coming from CE MDR-certified medical devices, Withings has become one of the few connected health companies to combine international scale, clinical credibility, and profitability.

France and Europe: Accelerating Markets

Germany, France, and the United Kingdom are Withings’ leading European markets. France represents Withings’ third largest market worldwide and its second largest in Europe, after Germany.

This positioning is the result of a deliberate strategy: combining French engineering with clinical rigor recognized by European medical institutions and certification bodies. Backed by €61 million in funding since 2019 and a team of 311 people, Withings offers a range of CE MDR-marked devices with no direct equivalent on the European market, almost all of which are compatible with the digital healthcare pathways currently being deployed. This momentum is accelerating: the Withings+ subscription service has nearly doubled its revenue by 2025.

Of its 15 million active users worldwide, Withings devices recorded over one billion health measurements by 2025, 360 million of which were clinical or medical measurements. More than 3.6 million users are currently classified as medical users, compared to a fraction of that number at the time of the 2018 acquisition.

Withings Health Solutions and Clinical Research

The Withings Health Solutions division offers remote monitoring and data analytics solutions to healthcare providers, digital health programs, hospital networks, insurers, and clinical research organizations in Europe and the United States, representing 17% of Withings’ total revenue. Prior to the acquisition, Withings had approximately 26,000 B2B patients enrolled in its programs. This number now exceeds one million. Healthcare facilities, insurers, and clinical research organizations have chosen to deploy Withings devices for their patients.

Between 2018 and 2025, Withings consistently reinvested between 20% and 27% of its annual revenue in research and development—roughly double the consumer electronics industry average. Since the 2018 acquisition, the annual volume of clinical publications involving Withings devices has reached a record high of 31 studies by 2025. To date, 150 clinical articles have been published in collaboration with world-renowned institutions, including the University of California San Francisco, the Mayo Clinic, and Northwestern University.

“We have always believed that health deserves better than fitness trackers. Achieving profitability in 2025 proves that it is possible to build a sustainable company on rigorous clinical foundations, serving both patients and physicians. Withings is a French company, and this credibility has been built here, from the very beginning.” Eric Carreel, President and Co-founder of Withings.

__

(Featured image by Mufid Majnun via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in Finyear. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.